NO20020764L - Benzosyrederivater for behandling av diabetes mellitus - Google Patents
Benzosyrederivater for behandling av diabetes mellitusInfo
- Publication number
- NO20020764L NO20020764L NO20020764A NO20020764A NO20020764L NO 20020764 L NO20020764 L NO 20020764L NO 20020764 A NO20020764 A NO 20020764A NO 20020764 A NO20020764 A NO 20020764A NO 20020764 L NO20020764 L NO 20020764L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- benzoic acid
- acid derivatives
- diabetes mellitus
- mellitus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9919413.6A GB9919413D0 (en) | 1999-08-18 | 1999-08-18 | Chemical compounds |
PCT/GB2000/003126 WO2001012612A1 (en) | 1999-08-18 | 2000-08-14 | Benzoic acid derivatives for the treatment of diabetes mellitus |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20020764D0 NO20020764D0 (no) | 2002-02-15 |
NO20020764L true NO20020764L (no) | 2002-04-17 |
Family
ID=10859285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020764A NO20020764L (no) | 1999-08-18 | 2002-02-15 | Benzosyrederivater for behandling av diabetes mellitus |
Country Status (15)
Country | Link |
---|---|
US (1) | US6787556B1 (no) |
EP (1) | EP1210339A1 (no) |
JP (1) | JP2003507372A (no) |
KR (1) | KR20020087382A (no) |
CN (1) | CN1379766A (no) |
AU (1) | AU766790B2 (no) |
BR (1) | BR0013374A (no) |
CA (1) | CA2381090A1 (no) |
GB (1) | GB9919413D0 (no) |
IL (1) | IL147822A0 (no) |
MX (1) | MXPA02001597A (no) |
NO (1) | NO20020764L (no) |
NZ (1) | NZ517060A (no) |
WO (1) | WO2001012612A1 (no) |
ZA (1) | ZA200200670B (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
ATE367812T1 (de) * | 2001-06-20 | 2007-08-15 | Wyeth Corp | Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1) |
TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
WO2004052855A2 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
CN1726191A (zh) * | 2002-12-10 | 2006-01-25 | 惠氏公司 | 用作纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代的吲哚氧代-乙酰氨基乙酸衍生物 |
UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
ES2268480T3 (es) * | 2002-12-10 | 2007-03-16 | Wyeth | Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
JP2006510673A (ja) * | 2002-12-10 | 2006-03-30 | ワイス | プラスミノゲンアクティベータインヒビター1(pai−1)のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換1h−インドール−3−イルグリオキシル酸誘導体 |
US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7411083B2 (en) * | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
RU2007106869A (ru) * | 2004-08-23 | 2008-09-27 | Вайет (Us) | Тиазол-нафтиловые кислоты как ингибиторы ингибитора активации плазминогена-1 |
WO2006023864A1 (en) * | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
KR20070055563A (ko) * | 2004-08-23 | 2007-05-30 | 와이어쓰 | 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(pai-1)의 조절제로서의옥사졸로-나프틸 산 |
US20090137637A1 (en) * | 2004-12-08 | 2009-05-28 | Pfizer Inc. | Tetrazolyl-Methylene Amino Acid Derivatives |
BRPI0614340A2 (pt) * | 2005-08-17 | 2011-04-12 | Wyeth Corp | indóis substituìdos e métodos de seu uso |
NZ566876A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals |
US20090298897A1 (en) * | 2006-01-17 | 2009-12-03 | Marina Cools | Treatment of Inflammatory Disorders With Triazole Compounds |
JP2010502719A (ja) | 2006-09-08 | 2010-01-28 | ロード アイランド ホスピタル | アルコール誘発性脳疾患の治療、予防および回復 |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
SG190433A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
DK2637668T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
CN103304504B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一种抗糖尿病化合物、其制备方法和用途 |
US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
ES2861503T3 (es) | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234942A (en) * | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
GB9417532D0 (en) * | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
HUP9900424A2 (hu) * | 1996-01-22 | 1999-05-28 | Fujisawa Pharmaceutical Co., Ltd. | Tiazolil-benzfurán-származékok és a vegyületeket tartalmazó gyógyászati készítmények |
-
1999
- 1999-08-18 GB GBGB9919413.6A patent/GB9919413D0/en not_active Ceased
-
2000
- 2000-08-14 AU AU65823/00A patent/AU766790B2/en not_active Ceased
- 2000-08-14 IL IL14782200A patent/IL147822A0/xx unknown
- 2000-08-14 WO PCT/GB2000/003126 patent/WO2001012612A1/en not_active Application Discontinuation
- 2000-08-14 CA CA002381090A patent/CA2381090A1/en not_active Abandoned
- 2000-08-14 EP EP00953309A patent/EP1210339A1/en not_active Withdrawn
- 2000-08-14 US US10/048,392 patent/US6787556B1/en not_active Expired - Fee Related
- 2000-08-14 MX MXPA02001597A patent/MXPA02001597A/es unknown
- 2000-08-14 BR BR0013374-4A patent/BR0013374A/pt not_active IP Right Cessation
- 2000-08-14 NZ NZ517060A patent/NZ517060A/en unknown
- 2000-08-14 CN CN00814330A patent/CN1379766A/zh active Pending
- 2000-08-14 JP JP2001517510A patent/JP2003507372A/ja active Pending
- 2000-08-14 KR KR1020027002018A patent/KR20020087382A/ko not_active Application Discontinuation
-
2002
- 2002-01-24 ZA ZA200200670A patent/ZA200200670B/en unknown
- 2002-02-15 NO NO20020764A patent/NO20020764L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US6787556B1 (en) | 2004-09-07 |
NO20020764D0 (no) | 2002-02-15 |
MXPA02001597A (es) | 2002-07-02 |
WO2001012612A1 (en) | 2001-02-22 |
BR0013374A (pt) | 2002-05-07 |
AU6582300A (en) | 2001-03-13 |
JP2003507372A (ja) | 2003-02-25 |
GB9919413D0 (en) | 1999-10-20 |
ZA200200670B (en) | 2003-06-25 |
IL147822A0 (en) | 2002-08-14 |
EP1210339A1 (en) | 2002-06-05 |
NZ517060A (en) | 2003-11-28 |
CN1379766A (zh) | 2002-11-13 |
AU766790B2 (en) | 2003-10-23 |
KR20020087382A (ko) | 2002-11-22 |
CA2381090A1 (en) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20020764L (no) | Benzosyrederivater for behandling av diabetes mellitus | |
NO20022087D0 (no) | Fremgangsmåte for behandling av diabetes | |
ZA200300889B (en) | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia. | |
NO20006630D0 (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
NO20014379L (no) | Anvendelse av Xenon for behandling av Neurointoksikasjoner | |
NO20013369D0 (no) | Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon | |
NO20013380D0 (no) | 2-aminobenzoksazinonderivater for behandling av fedme | |
NO20021474L (no) | Forbindelser for behandling av ischemi | |
NO20021963D0 (no) | Anvendelse av organiske forbindelser av sykdom | |
NO20022979D0 (no) | Anvendelse av organiske forbindelser | |
NO20054408D0 (no) | 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose | |
NO20013381D0 (no) | 2-oksybenzoksazinonderivater for behandling av fedme | |
NO20010365L (no) | Fremgangsmåte for fremstilling av orto-alkylerte benzosyrederivater | |
EE200200305A (et) | Südame arütmiate ravis kasutatavad uued asabitsüklooktaani derivaadid | |
NO20021368L (no) | Fremgangsmåte for fremstilling av fenyleddiksyre derivater | |
NO20020784L (no) | Medikament for behandling av brudd | |
NO20012541D0 (no) | Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner | |
AU4937699A (en) | Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing | |
NO20012612L (no) | Isonipecotamider for behandlingen av integrin-formidlede sykdommer | |
NO20025883L (no) | Tiazolidinonsalt for behandling av diabetes mellitus | |
EP1517883B8 (en) | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | |
NO20012540D0 (no) | Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner | |
PL375080A1 (en) | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | |
NO20013385L (no) | S-nitrosotioler som midler for behandling av sirkulatoriske dysfunksjoner | |
EP1177789A3 (en) | Use of phytanic acid for the treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |